| 摘要: | 在原發性中樞神經系統（central nervous system ,CNS）腫瘤當中，膠質瘤是目前最常見的，約每 100,000 人當中約有4.5 人會發生，平均生存時間於52 週。目前尚未有針對膠質瘤的標靶藥物可以使 用，所以目前治療方式以手術切除為主。目前手術治療的過程中，由於腫瘤邊緣難以判定，因此，手 術切除惡性膠質瘤最重要挑戰就是如何精準切除正常腦組織與腫瘤組織的界線，切除不完全將導致復 發的可能機率。截至目前為止，有越來越多的證據顯示腫瘤切除範圍與手術後復發的機率呈現相當的 反比關係。因此，在手術過程中清楚地識別腫瘤區域將非常有助於腫瘤切除的完整度。利用腫瘤的特 殊表現蛋白來呈現分子影像偵測與診斷在現階段仍無法提供手術前的評估與輔助，更無法提供治療的 功能。因此，發展一個準確可辨識腦瘤的高效能分子影像探針將可以大幅改善改變以往偵測與診斷方 法的缺點。本計畫透過台灣和波蘭團隊的合作，將發展一種對腦瘤具有專一性的磁振造影(MR)顯影劑 來進行神經膠質瘤的偵測、診斷與治療。
Among primary central nervous system (CNS) neoplasia, high-grade glioma is the most common, occurring at an incidence of approximately 4.5 per 100,000. While there are long-term survivors, mean survival remains less than 52 weeks. This poor prognosis in part reflects difficult visualization of tumor margins, such that surgical resection is incomplete and there is a failure of therapeutic agents to reach the target cells. A major challenge during the surgical removal of malignant glioma is differentiating tumor cells from normal brain at the tumor/brain interface. As a result, surgical resection is often less than desired. This is important, as there is increasing evidence that the extent of resection correlates with outcome. Therefore, clearly identifying tumor cells during surgery would facilitate optimal resection. Imaging modalities are currently unable to efficiently take full advantage of unique tumor cell protein expression, for pre-operative diagnosis, intraoperative resection control and monitoring or delivering adjuvant therapies. Developing such an agent specific for high-grade glioma would revolutionize the diagnosis and treatment of patients with this condition. Therefore the aim of the project is to develop Magnetic Resonance Imaging (MRI) contrast agent that reduces both relaxation times for early tumor detection. |
